NAS:CLLS (France)  
Cellectis SA logo

Cellectis SA

$ 2.30 -0.13 (-5.35%) 08:08 PM EST
P/E:
At Loss
P/B:
0.66
Market Cap:
$ 111.36M
Enterprise V:
$ 75.88M
Volume:
93.98K
Avg Vol (2M):
114.87K
Also Trade In:
Volume:
93.98K
Market Cap $:
111.36M
PE Ratio:
At Loss
Avg Vol (2-Month):
114.87K
Enterprise Value $:
75.88M
PB Ratio:
0.66
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Financials (Next Earnings Date:2022-11-04 Est.)

CLLS's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CLLS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 23.562
EPS (TTM) ($) -2.89
Beta 2.21
Volatility % 52.56
14-Day RSI 30.19
14-Day ATR ($) 0.206065
20-Day SMA ($) 2.9735
12-1 Month Momentum % -73.87
52-Week Range ($) 2.25 - 13.12
Shares Outstanding (Mil) 45.51

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cellectis SA Filings

Document Form Filing Date
No Filing Data

Cellectis SA Analysis

Share your research

Headlines

See More
No news.